Lenz Therapeutics (LENZ) shares plummeted 11.2% in early trading on Tuesday after the company reported disappointing Q4 earnings. Analysts had anticipated a loss of $0.90 per share with sales of $3.1 million, but Lenz fell short, posting a loss of $1.16 per share on only $1.6 million in revenue. The company’s new product, VIZZ, aimed at treating presbyopia, launched in October 2025, but initial sales figures did not meet market expectations.
The underwhelming performance is primarily attributed to a significant increase in selling, general, and administrative expenses, which quadrupled during the product’s launch phase. While Lenz claims to be on track for 45,000 prescriptions by the end of Q1 2026, the lack of clarity on prescription growth and future guidance has left investors uncertain about the product’s market acceptance.
For market professionals, the key takeaway is the potential volatility in Lenz’s stock as investors digest the implications of high initial costs and unclear growth trajectories for VIZZ.
Source: fool.com